Search

Your search keyword '"Bertoletti F"' showing total 69 results

Search Constraints

Start Over You searched for: Author "Bertoletti F" Remove constraint Author: "Bertoletti F"
69 results on '"Bertoletti F"'

Search Results

1. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry

4. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry

5. Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)

6. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

7. DOP78 Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)

9. P104 Inflammatory complications of the pouch, and therapetic requirements after colectomy in patients with ulcerative colitis. Results from the RESERVO Study of GETECCU

10. P276 Influence of vedolizumab on extraintestinal manifestations in Inflammatory Bowel Disease: a nationwide multicenter study of the GETECCU Eneida registry

11. P458 Effectiveness of biological therapy for pouchitis and other inflammatory complications ot the pouch. And the question of a second Anti-TNF after failure? Results from the RESERVO Study of GETECCU

12. P372 Effectiveness and safety of immunosuppressants for pouch disorders: results from the RESERVO Study of GETECCU

13. P531 SARS-CoV-2 infection in Elderly patients with Inflammatory Bowel Disease with or without immunosuppressants during the first year of the pandemic. An observational, descriptive, cohort study

14. Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-alpha: results from the ENEIDA registry

15. Inflammatory complications of the pouch, and therapetic requirements after colectomy in patients with ulcerative colitis. Results from the RESERVO Study of GETECCU

18. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients

19. P584 Use of mycophenolate mofetil in inflammatory bowel disease: results from the ENEIDA registry

21. P559 Real-life experience with long-term maintenance of golimumab in ulcerative colitis patients

22. PANICULITIS PANCREÁTICA RECURRENTE ASOCIADA A PANCREATITIS BILIAR. REPORTE DE UN CASO Y REVISIÓN DE LA LITERATURA.

23. [Lympho-epithelial carcinoma (malignant lympho-epithelial lesions) of the parotid gland. Description of a case with detection of EBV by in situ hybridization]

24. [Hemangiopericytoma-like tumor (HPCLT) of the nasal cavity: morphological, immunohistochemical, and ultrastructural features]

26. PANICULITIS PANCREÁTICA RECURRENTE ASOCIADA A PANCREATITIS BILIAR. REPORTE DE UN CASO Y REVISIÓN DE LA LITERATURA.

27. Tyrosine kinases as essential cellular cofactors and potential therapeutic targets for human immunodeficiency virus infection

28. Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

29. Chronic Cough and Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome (CANVAS): Screening for Mutations in Replication Factor C Subunit 1 (RFC1).

30. Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project.

31. Duration of smoking cessation in patients with inflammatory bowel disease.

32. Perception of the impact of intravenous biological treatment on the work and professional environment in patients with inflammatory bowel disease.

33. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU.

34. Clinical and functional characteristics, possible causes, and impact of chronic cough in patients with cerebellar ataxia, neuropathy, and bilateral vestibular areflexia syndrome (CANVAS).

35. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.

36. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.

37. Perception of the need for dietary advice and dietary modifications in inflammatory bowel disease patients.

38. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII).

39. Predictability of adverse outcomes in hypertensive disorders of pregnancy: a multicenter prospective cohort study.

40. Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease.

41. Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry.

42. Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-α: results from the ENEIDA registry.

43. A Role for Human DNA Polymerase λ in Alternative Lengthening of Telomeres.

44. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients.

45. Dietary Fat Patterns and Outcomes in Acute Pancreatitis in Spain.

46. Impact of pain associated with the subcutaneous administration of adalimumab.

47. UBR5 interacts with the replication fork and protects DNA replication from DNA polymerase η toxicity.

48. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis.

49. Phosphorylation regulates human polη stability and damage bypass throughout the cell cycle.

50. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.

Catalog

Books, media, physical & digital resources